| Literature DB >> 28857715 |
M F Ugarte-Gil1,2, D Wojdyla3, C A Pastor-Asurza1,4, R V Gamboa-Cárdenas1, E M Acevedo-Vásquez1,4, L J Catoggio5, M A García6, E Bonfá7, E I Sato8, L Massardo9, V Pascual-Ramos10, L A Barile11, G Reyes-Llerena12, A Iglesias-Gamarra13, J F Molina-Restrepo14, R Chacón-Díaz15, G S Alarcón16, B A Pons-Estel17.
Abstract
Purpose The purpose of this paper is to determine the factors predictive of flares in systemic lupus erythematosus (SLE) patients. Methods A case-control study nested within the Grupo Latino Americano De Estudio de Lupus (GLADEL) cohort was conducted. Flare was defined as an increase ≥4 points in the SLEDAI. Cases were defined as patients with at least one flare. Controls were selected by matching cases by length of follow-up. Demographic and clinical manifestations were systematically recorded by a common protocol. Glucocorticoid use was recorded as average daily dose of prednisone and antimalarial use as percentage of time on antimalarial and categorized as never (0%), rarely (>0-25%), occasionally (>25%-50%), commonly (˃50%-75%) and frequently (˃75%). Immunosuppressive drugs were recorded as used or not used. The association between demographic, clinical manifestations, therapy and flares was examined using univariable and multivariable conditional logistic regression models. Results A total of 465 cases and controls were included. Mean age at diagnosis among cases and controls was 27.5 vs 29.9 years, p = 0.003; gender and ethnic distributions were comparable among both groups and so was the baseline SLEDAI. Independent factors protective of flares identified by multivariable analysis were older age at diagnosis (OR = 0.929 per every five years, 95% CI 0.869-0.975; p = 0.004) and antimalarial use (frequently vs never, OR = 0.722, 95% CI 0.522-0.998; p = 0.049) whereas azathioprine use (OR = 1.820, 95% CI 1.309-2.531; p < 0.001) and SLEDAI post-baseline were predictive of them (OR = 1.034, 95% CI 1.005-1.064; p = 0.022). Conclusions In this large, longitudinal Latin American cohort, older age at diagnosis and more frequent antimalarial use were protective whereas azathioprine use and higher disease activity were predictive of flares.Entities:
Keywords: Systemic lupus erythematosus; antimalarials; flares; risk factors
Mesh:
Substances:
Year: 2017 PMID: 28857715 DOI: 10.1177/0961203317728810
Source DB: PubMed Journal: Lupus ISSN: 0961-2033 Impact factor: 2.911